Encorafenib (Braftovi®) is a prescription medicine used in combination with binimetinib (Mektovi®) to treat people with a type of cancer called melanoma that has spread to other parts of the body (advanced melanoma) and cannot be removed by surgery. It is a kinase inhibitor that works by blocking certain proteins that help cancer cells grow and spread.
Encorafenib is a medication used to treat specific types of cancers, particularly:
- Melanoma: A type of skin cancer that develops from pigment-producing cells (melanocytes).
- Non-small cell lung cancer (NSCLC): A common type of lung cancer that doesn't start in the small, round cells.
How it Works:
Encorafenib belongs to a class of drugs called BRAF inhibitors. BRAF is a protein involved in a cell signaling pathway that regulates cell growth and division. In some cancers, mutations in the BRAF gene can cause uncontrolled cell growth. Encorafenib works by blocking the BRAF protein, interrupting this signaling pathway and hindering the growth and spread of cancer cells.
Uses of Encorafenib:
Encorafenib is typically used in combination with other medications for the treatment of BRAF mutation-positive cancers. Here are some specific uses:
- Melanoma: Encorafenib, combined with another medication called binimetinib, is approved for the treatment of adults with advanced or metastatic melanoma that has a BRAF V600E or V600K mutation.
- NSCLC: Encorafenib, along with another drug called erlotinib, is approved for the treatment of adults with advanced NSCLC that has a specific BRAF mutation.
Important Considerations:
- Targeted Therapy: Encorafenib is a targeted therapy effective only for cancers with the specific BRAF mutations. A doctor will perform a genetic test to confirm the presence of this mutation before using Encorafenib.
- Side Effects: Encorafenib can cause some serious side effects, including:
- Skin problems like dryness, rash, and hair loss
- Fatigue
- Diarrhea
- Nausea and vomiting
- Joint pain
- Eye problems
- Increased risk of bleeding
- In rare cases, Encorafenib-associated encephalitis (EAE), a serious brain inflammation, can occur.
- Pregnancy and Breastfeeding: Encorafenib can harm an unborn baby and should not be used during pregnancy. It's also not recommended for women who are breastfeeding.
Brand Name:
Encorafenib is available under the brand name:
- Tafinlar®
Disclaimer: This information is for educational purposes only and should not be interpreted as medical advice. If you have any questions about Encorafenib, its side effects, or whether it's the right treatment for you, consult your doctor. They can provide tailored guidance based on your specific medical situation.